A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the bioequivalence between two formulations of sacubitril/valsartan 24 mg/26 mg
film-coated tablets, Entresto 50 mg (Reference) and Sacubitril and Valsartan Sodium Tablets
24 mg/26 mg (Test), after a single oral dose administration in healthy Thai subjects under
fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Dr. Reddy's Laboratories (Thailand) Limited
Treatments:
Sacubitril and valsartan sodium hydrate drug combination Valsartan